Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$22.71 -1.0%	$18.84	$13.40 ▼ $25.23	$3.80B	0.64	1.96 million shs	6.66 million shs
DOCS Doximity	$57.47 +0.8%	$55.53	$25.00 ▼ $85.21	$10.80B	1.32	2.15 million shs	2.64 million shs
MMSI Merit Medical Systems	$91.98 -1.0%	$94.53	$82.04 ▼ $111.45	$5.44B	0.66	534,892 shs	960,835 shs
NARI Inari Medical	$79.97	$79.97	$39.76 ▼ $79.99	$4.68B	1.02	1.39 million shs	N/A

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+4.61%	+3.32%	+31.80%	+48.43%
DOCS Doximity	0.00%	+2.79%	+12.56%	-13.43%	+108.84%
MMSI Merit Medical Systems	0.00%	-1.06%	-3.56%	-12.13%	+11.88%
NARI Inari Medical	0.00%	0.00%	0.00%	0.00%	+73.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.6407 of 5 stars	3.3	1.0	0.0	2.6	4.2	2.5
DOCS Doximity	2.2945 of 5 stars	2.3	0.0	0.0	2.2	4.2	1.3
MMSI Merit Medical Systems	4.0922 of 5 stars	3.5	1.0	3.8	2.3	2.5	1.3
NARI Inari Medical	0.2825 of 5 stars	1.1	0.0	0.0	0.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.69	Moderate Buy	$26.79	17.95% Upside
DOCS Doximity	2.59	Moderate Buy	$62.84	9.34% Upside
MMSI Merit Medical Systems	3.00	Buy	$109.11	18.62% Upside
NARI Inari Medical	2.14	Hold	$69.22	-13.44% Downside

Current Analyst Ratings Breakdown

Latest DOCS, ACAD, MMSI, and NARI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
6/2/2025	DOCS Doximity	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$80.00
5/27/2025	DOCS Doximity	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$63.00 ➝ $60.00
5/23/2025	MMSI Merit Medical Systems	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$106.00 ➝ $110.00
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00
5/21/2025	DOCS Doximity	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$80.00 ➝ $50.00
5/21/2025	MMSI Merit Medical Systems	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$108.00 ➝ $112.00
5/21/2025	MMSI Merit Medical Systems	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$106.00 ➝ $108.00
5/20/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.97	$0.70 per share	32.22	$4.40 per share	5.16
DOCS Doximity	$570.40M	18.93	$0.71 per share	81.32	$5.52 per share	10.41
MMSI Merit Medical Systems	$1.36B	4.01	$5.61 per share	16.41	$23.67 per share	3.89
NARI Inari Medical	$493.63M	9.48	$0.09 per share	906.95	$8.07 per share	9.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	16.58	29.88	4.85	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
DOCS Doximity	$147.58M	$1.11	57.47	53.71	4.10	36.60%	21.75%	18.64%	N/A
MMSI Merit Medical Systems	$120.36M	$2.04	45.09	24.53	3.03	8.81%	15.52%	8.72%	7/30/2025 (Estimated)
NARI Inari Medical	-$1.64M	-$1.35	N/A	727.00	N/A	-13.68%	-10.09%	-6.60%	N/A

Latest DOCS, ACAD, MMSI, and NARI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	N/A	DOCS Doximity	$0.27	$0.38	+$0.11	N/A	N/A	N/A
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
4/24/2025	Q1 2025	MMSI Merit Medical Systems	$0.75	$0.86	+$0.11	$0.49	$352.57 million	$355.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DOCS Doximity	N/A	N/A	N/A	N/A	N/A
MMSI Merit Medical Systems	N/A	N/A	N/A	N/A	N/A
NARI Inari Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
DOCS Doximity	N/A	8.74	8.74
MMSI Merit Medical Systems	0.51	4.87	3.26
NARI Inari Medical	N/A	1.77	1.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
DOCS Doximity	87.19%
MMSI Merit Medical Systems	99.66%
NARI Inari Medical	90.98%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
DOCS Doximity	37.40%
MMSI Merit Medical Systems	3.70%
NARI Inari Medical	10.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	120.00 million	Optionable
DOCS Doximity	890	187.83 million	116.87 million	Not Optionable
MMSI Merit Medical Systems	7,400	59.10 million	56.91 million	Optionable
NARI Inari Medical	800	58.54 million	52.34 million	Optionable

DOCS, ACAD, MMSI, and NARI Headlines

Recent News About These Companies

Route 92 Medical Appoints Medtech Industry Veterans Mitch Hill and Lucas Buchanan to its Board of Directors

June 18, 2025 | finance.yahoo.com

American Century Small Cap Growth Fund Q1 2025 Commentary

June 11, 2025 | seekingalpha.com

Thrombectomy system removes clots, improves quality of life for patients with PE

May 20, 2025 | healio.com

The top nitinol cardiac medtech news of 2025 (so far)

May 13, 2025 | medicaldesignandoutsourcing.com

Stryker outlines 2025 growth targets with 8.5%-9.5% organic sales growth and $13.20-$13.45 EPS

May 2, 2025 | msn.com

Expert Testimony Supporting POPR Can Be An Effective Strategy

April 21, 2025 | jdsupra.com

Volta Medical Appoints Bill Hoffman as Executive Chairman of the Board of Directors

April 8, 2025 | finance.yahoo.com

8 spine, orthopedic acquisitions in Q1

March 27, 2025 | beckersspine.com

Okami Medical Announces Portfolio Expansion with the Addition of the SENDERO® MAX Delivery Catheter

March 26, 2025 | finance.yahoo.com

How Is Inari Medical Inc. (NASDAQ:NARI) Positioned in the Medical Devices Sector?

March 25, 2025 | kalkinemedia.com

If You Could Only Hold 3 Investments for Life, Consider These (NARI)

March 10, 2025 | marketbeat.com

Stryker’s Inari Medical Launches Artix Thrombectomy System

March 7, 2025 | evtoday.com

Stryker’s Inari Medical launches Artex thrombectomy system

March 7, 2025 | massdevice.com

Inari Medical introduces thrombectomy system for arterial thrombus cases

March 7, 2025 | msn.com

Inari Medical acquisition could provide Stryker with foothold in peripheral vascular market

February 28, 2025 | expresshealthcare.in

Wearable defibrillator maker Kestra Medical plots $150M IPO

February 26, 2025 | fiercebiotech.com

Stryker grows cardiovascular division with Inari Medical acquisition

February 24, 2025 | medicaldevice-network.com

Stryker Completes Acquisition of Inari

February 20, 2025 | evtoday.com

Stryker concludes Inari Medical acquisition for $4.9bn

February 20, 2025 | finance.yahoo.com

Stryker completes Inari Medical acquisition

February 20, 2025 | beckersspine.com

Inari Medical, Inc. (NARI): the Best Performing Healthcare Stock So Far in 2025

February 20, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOCS, ACAD, MMSI, and NARI Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.71 -0.24 (-1.05%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$22.64 -0.07 (-0.33%)

As of 06/20/2025 07:08 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Doximity NASDAQ:DOCS

$57.47 +0.43 (+0.76%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$56.62 -0.86 (-1.49%)

As of 06/20/2025 07:59 PM Eastern

Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.

Merit Medical Systems NASDAQ:MMSI

$91.98 -0.97 (-1.04%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$91.95 -0.03 (-0.03%)

As of 06/20/2025 05:28 PM Eastern

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.

Inari Medical NASDAQ:NARI

$79.97 0.00 (0.00%)

As of 02/19/2025

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time